The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness

I Glenn Cohen; Holly Fernandez Lynch; Amy L McGuire

doi:10.1001/jama.2026.11892

The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness

JAMA. 2026 Jul 1. doi: 10.1001/jama.2026.11892. Online ahead of print.

Authors

I Glenn Cohen^{1

2}, Holly Fernandez Lynch³, Amy L McGuire⁴

Affiliations

¹ Harvard Law School, Cambridge, Massachusetts.
² The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University, Cambridge, Massachusetts.
³ Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁴ Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas.

PMID: 42384415
DOI: 10.1001/jama.2026.11892

No abstract available

Plain language summary

This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.